Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations

Cancer Research

Volumn 68, Issue 16, 2008, Pages 6789-6796

  Yan, Wensheng ^a   Liu, Gang ^a   Scoumanne, Ariane ^a   Chen, Xinbin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR OF DIFFERENTIATION 2; PROTEIN P53; ID2 PROTEIN, HUMAN; LUCIFERASE; MESSENGER RNA; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; COLON ADENOCARCINOMA; COLON CANCER; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE REPRESSION; HUMAN; HUMAN CELL; INDUCED MUTATION; KNOCKOUT GENE; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FAMILY; PROTEIN SYNTHESIS; TUMOR CELL; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CLONOGENIC ASSAY; COLON TUMOR; DRUG ANTAGONISM; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; MUTATION; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; BLOTTING, NORTHERN; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLONIC NEOPLASMS; COLONY-FORMING UNITS ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 2; LUCIFERASES; MUTATION; PANCREATIC NEOPLASMS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 53049095294     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0810     Document Type: Article

References (33)

1. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-61.
2. Loehberg CR, Thompson T, Kastan MB, et al. Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. Cancer Res 2007;67:12026-33.
3. Lang GA, Iwakuma T, Suh YA, et al. gain-of-function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119:861-72.
4. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain-of-function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006;25:304-9.
5. Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain-of-function in two mouse models of Li-Fraumeni syndrome. Cell 2004;119:847-60.
6. Heinlein C, Krepulat F, Lohler J, Speidel D, Deppert W, Tolstonog GV. Mutant p53(R270H) gain-of-function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. Int J Cancer 2008:122:1701-9.
7. Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 1998;18:3735-43.
8. Atema A, Chene P. The gain-of-function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers. Cancer Lett 2002;185:103-9.
9. Scian MJ, Stagliano KE, Anderson MA, et al. Tumorderived p53 mutants induce NF-kB2 gene expression. Mol Cell Biol 2005:25:10097-110.
10. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM. Id proteins in cell growth and tumorigenesis. Cancer Cell 2003;3:525-30.
11. Coppe JP, Smith AP, Desprez PY. Id proteins in epithelial cells. Exp Cell Res 2003;285:131-45.
12. Rothschild G, Zhao X, lavarone A, Lasorella A. E proteins and Id2 converge on p57Kip2 to regulate cell cycle in neural cells. Mol Cell Biol 2006;26:4351-61.
13. Lasorella A, lavarone A. The protein ENH is a cytoplasmic sequestration factor for Id2 in normal and tumor cells from the nervous system. Proc Natl Acad Sci USA 2006;103:4976-81.
14. Newton TR, Parsons PG, Lincoln DJ, et al. Expression profiling correlates with treatment response in women with advanced serous epithelial ovarian cancer. Int J Cancer 2006;119:875-83.
15. Hua H, Zhang YQ, Dabernat S, et al. BMP4 regulates pancreatic progenitor cell expansion through Id2. J Biol Chem 2006;281:13574-80.
16. Itahana Y, Singh J, Sumida T, et al. Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells. Cancer Res 2003;63:7098-105.
17. Russell RG, Lasorella A, Dettin LE, lavarone A. Id2 drives differentiation and suppresses tumor formation in the intestinal epithelium. Cancer Res 2004;64:7220-5.
18. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents [see comments]. J Clin Invest 1999;104:263-9.
19. Yan W, Chen X. Targeted repression of bone morphogenetic protein 7, a novel target of the p53 family, triggers proliferative defect in p53-deficient breast cancer cells. Cancer Res 2007;67:9117-24.
20. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
21. Liu G, Xia T, Chen X. The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein. J Biol Chem 2003;278:17557-65.
22. Nozell S, Chen X p21B, a variant of p21(Wafl/Cipl), is induced by the p53 family. Oncogene 2002:21:1285-94.
23. Chen X, Bargonetti J, Prives C. p53, through p21 (WAF1/CIP1), induces cyclin DI synthesis. Cancer Res 1995;55:4257-63.
24. Zhu J, Zhou W, Jiang J, Chen X. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J Biol Chem 1998;273:13030-6.
25. Peart MJ, Prives C. Mutant p53 gain-of-function: the NF-Y connection. Cancer Cell 2006;10:173-4.
26. Onken MD, Ehlers JP, Worley LA, Makita J, Yokota Y, Harbour JW. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res 2006;66:4602-9.
27. Stighall M, Manetopoulos C, Axelson H, Landberg G. High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells. Int J Cancer 2005;115:403-11.
28. Lasorella A, Rothschild G, Yokota Y, Russell RG, lavarone A. Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice. Mol Cell Biol 2005; 25:3563-74.
29. Kowanetz M, Valcourt U, Bergstrom R, Heldin CH, Moustakas A. Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor β and bone morphogenetic protein. Mol Cell Biol 2004;24:4241-54.
30. Zambetti GP. The p53 mutation "gradient effect" and its clinical implications. J Cell Physiol 2007;213:370-3.
31. Weisz L, Damalas A, Liontos M, et al. Mutant p53 enhances nuclear factor kB activation by tumor necrosis factor a in cancer cells. Cancer Res 2007;67:2396-401.
32. Di Agostino S, Strano S, Emiliozzi V, et al. gain-offunction of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006;10:191-202.
33. Batista LF, Roos WP, Christmann M, Menck CF, Kaina B. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 2007;67:11886-95.